Active infection or an unexplained fever > 38.5 degrees Celsius (C) during screening visits or on the first scheduled day of dosing (at the discretion of the investigator, patients with tumor fever may be enrolled), which in the investigator’s opinion might compromise the patient’s participation in the trial or affect the study outcome
Presence of an active infection or with an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing, which in the investigator's opinion might compromise the patient's participation in the trial or affect the study outcome. At the discretion of the investigator, patients with tumor fever may be enrolled
Patients with active infection or with a fever > 38.50 C within 3 days of the first scheduled day of dosing;
Recent (within 30 days before enrollment) or concurrent yellow fever vaccination
Fever within 3 days prior to study enrollment.
Active infection within one-week prior to study, including unexplained fever
Patients with evidence of an active bacterial infection or with a fever ? 38.5 ºC (101.3 ºF) within 3 days of the first scheduled day of dosing
Patients must NOT have an active severe infection defined as:\r\n* A positive blood culture within 48 hours of study enrollment\r\n* A fever above 38.2 celsius (C) AND clinical signs of infection within 48 hours of study enrollment
RETREATMENT WITH MODIFIED T-CELLS EXCLUSION CRITERIA: Patients has an active severe infection defined as:\r\n* A positive blood culture within 48 hours of scheduled T cell infusion OR\r\n* A fever above 38.2 C AND clinical signs of infection within 48 hours of T cell infusion
Patients may not have fever (38.5*C) within 7 days of enrollment
Patients with active infection or with a fever > 38.5 degrees (^0) Celsius (C) within three days prior to the first treatment
Research participant does not have a fever exceeding 38.5 degrees Celsius (C); there is an absence of positive blood cultures for bacteria, fungus, or virus within 48-hours prior to T cell infusion and/or there aren’t any indications of meningitis
Subjects must NOT have an active severe infection defined as:\r\n* A positive blood culture within 48 hours of study enrollment\r\n* A fever above 38.2 Celsius (C) AND clinical signs of infection within 48 hours of study enrollment
Infection Criteria\r\n* Positive blood culture within 48 hours of study enrollment\r\n* Fever above 38.2 within 48 hours of study enrollment with clinical signs of infection; fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability\r\n* Active fungal, viral, bacterial, or protozoal infection requiring IV treatment; chronic prophylaxis therapy to prevent infections is allowed
Subjects must NOT have an active severe infection defined as:\r\n* A positive blood culture within 48 hours of study enrollment\r\n* A fever above 38.2 Celsius (C) AND clinical signs of infection within 48 hours of study enrollment
Patients with uncontrolled intercurrent illness, active or uncontrolled infections, or a fever > 38.5 degrees Celsius (C) that has not been evaluated for infection up to the day of initial dosing; patients with documented history of tumor fever are accepted provided acute or chronic infection has been excluded as possible cause of the fever
Active infection causing fever.
Subjects with active infection or with a fever > 38.50 degrees Celsius (C) within t3 days prior to the first scheduled treatment
Registered patients with an active infection or with a fever of ? 38.5 Celsius degrees (C) within 24 hours of the first scheduled day of protocol initiation will be excluded until their infection and/or fever resolves
Persistent fever (>24 hours) documented by repeated measurement or active, uncontrolled infection within 4 weeks of enrollment.
New or active infection as determined by fever, unexplained pulmonary infiltrate or sinusitis on radiographic assessment; infections diagnosed within 4 weeks of registration must be determined to be controlled or resolving prior to treatment
Current evidence of fever or untreated infection
Patients with uncontrolled active infections (fever >= 38 degrees Celsius [C], septic shock)
Patient must NOT have an active severe infection defined as:\r\n* A positive blood culture within 48 hours of study enrollment\r\n* A fever above 38.2 Celsius (C) AND clinical signs of infection within 48 hours of study enrollment
ELIGIBILITY CRITERIA FOR T-CELL PRODUCT INFUSION: Patients must NOT have an active severe infection defined as:\r\n* A positive blood culture within 48 hours of scheduled T cell infusion\r\n* A fever above 38.2 C AND clinical signs of infection within 48 hours of T cell infusion
RETREATMENT WITH MODIFIED T CELLS: Patient has an active severe infection defined as:\r\n* A positive blood culture within 48 hours of scheduled T cell infusion\r\n* A fever above 38.2 C AND clinical signs of infection within 48 hours of T cell infusion
Active infection or antibiotics within 48 hours prior to study enrollment, including unexplained fever (temp > 38.1°C), if deemed clinically significant by the treating physician.
Patients with an active infection or with a fever ? 38.5°C within 3 days of the first scheduled day of dosing.
Active infection or unexplained fever
Unexplained fever and/or untreated, active infection
Patients with active bacterial infections with systemic manifestations (malaise, fever, leucocytosis) are not eligible until completion of appropriate therapy.
Active infection or an unexplained fever >38.5°C during Screening or on the first scheduled day of dosing.
Patients with an active infection or with an unexplained fever during screening or on the first scheduled day of dosing;
Fever (> 38.1°C)
Persistent fever (>24 hours) documented by repeated measurement or active, uncontrolled infection within 4 weeks of enrollment.
Patients with neutropenic fever who have existing malignancy or have undergone hematopoietic stem cell transplantation; neutropenic fever is defined as the presence of neutropenia defined by: 1) absolute neutrophil count (ANC) < 500 cells/mm^3 or has an ANC that is expected to decrease to < 500 cells/mm^3 within 48 hours of trial entry and fever defined as: 2) single oral temperature measurement of > 101 degree Fahrenheit (F) (38.3 degree Celsius [C]) or a temperature of > 100.4 degree F (38.0 degree C) sustained over a 1-hour period
Fever suspected to be caused by a noninfectious cause (eg, fever related to drug or blood product administration)
Active infection =< 5 days prior to registration or fever > 38 degrees Celsius (C) on day of registration
Patients who have an active uncontrolled infection defined as: \r\n* Positive bacterial blood culture within 48 hours of study enrollment; \r\n* Fever above 38.2 degree Celsius (C) within 48 hours of study enrollment with clinical signs of infection; fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability\r\n* A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection\r\n* Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection as long as cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved; for patients with clostridium (c.) difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline\r\n* Active viral or protozoal infection requiring IV treatment
Active infection including known AIDS or Hepatitis C or with a fever ?38.5°C within 3 days prior to enrollment
Active infection: temperature > 100 Fahrenheit (F), fever of unknown origin, active symptoms or signs of infection as defined by the investigator
Patients with an active infection or with a fever >= 101.3 F within 3 days of the first scheduled day of protocol treatment
Presence of an active infection; patients with fever assessed to be \tumor fever\ but without active evidence of infection (e.g. blood cultures are negative) are eligible; in addition, patients who have an infection but without evidence of fever for 48 hours on antibiotics will be eligible
Subjects with an active severe infection or with an unexplained fever >38.5°C during screening visits or on their first day of study drug administration (at the discretion of the Investigator, subjects with tumor fever may be enrolled).
Patients with an active severe infection that required anti-infective therapy or with an unexplained fever >38.5°C during screening visits or on their first day of study drug administration (at the discretion of the Investigator, patients with tumor fever may be enrolled)
Active infection, including unexplained fever (temperature > 38.5 deg.C).
Persistent fever (> 24 hours) documented by repeated measurement =< 4 weeks prior to registration
Have received recent (within 28 days prior to randomization) yellow fever vaccination
Subjects with an active severe infection that required anti-infective therapy or with an unexplained fever >38.5°C during screening visits or on their first day of study drug administration (at the discretion of the Investigator, subjects with tumor fever may be enrolled).
Active infection or antibiotics within 48 hours prior to study enrollment, including unexplained fever (temp > 38.1°C), if deemed clinically significant by the treating physician.
Active infection =< 5 days prior to registration or fever > 38 degrees Celsius (C) on day of registration
Subjects with an active severe infection that required anti-infective therapy or with an unexplained fever >38.5°C during screening visits or on their first day of study drug administration (at the discretion of the Investigator, subjects with tumor fever may be enrolled).
Active infection or antibiotics within 48 hours prior to study enrollment, including unexplained fever (temp > 38.1°C) if deemed clinically significant by the treating physician.
New or active infection as determined by fever, unexplained pulmonary infiltrate or sinusitis on radiographic assessment; infections diagnosed within 4 weeks of registration must be determined to be controlled or resolving prior to treatment
Patients must have no fever or evidence of infection or other coexisting medical condition that would preclude protocol therapy
Active infection or fever > 38.5°C during screening visits or on the first scheduled day of dosing
Hydroxyurea-related fever.
Fever above 38.2 within 48 hours of study enrollment with clinical signs of infection.
Patients who have an active infection or with an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing (at the discretion of the investigator, patients with tumor fever may be enrolled.)
Patients with active infection or with a fever > 38.5 degrees Celsius (C) within three days prior to the first scheduled treatment
Active infection including known AIDS or Hepatitis C or with a fever ?38.5°C within 3 days prior to study enrollment
Patients with an active infection (i.e., clinical signs or symptoms, including, but not limited to: bleeding/pustulant skin infections; productive cough associated with fever) on antibiotics or with a fever >= 38.5° Celsius (C) within 3 days prior to registration (i.e. date when the patient signs the consent and/or the patient is registered in CORE)
Presence of an active infection or fever >= 38.5 C within 3 days of the first scheduled protocol treatment
Subjects with an active infection or with a fever >/+ 38.5 degrees C within 3 days of the first scheduled day of dosing for Cycle 1
Concomitant vaccination with yellow fever vaccine.
Patients with uncontrolled concurrent illness, active infection requiring i.v. antibiotics, or uncontrolled infections, or a fever > 38.5°C on the day of scheduled dosing
Active severe infection that required anti-infective therapy or with an unexplained fever >38.5°C during screening visits or on their first day of study drug administration (at the discretion of the Investigator, subjects with tumor fever may be enrolled)
Active infection or fever > 38.5°C during screening visits or on the first scheduled day of dosing
Patients with an active infection or with an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing. (At the discretion of the investigator, patients with tumor fever may be enrolled.)
Treatment with antibiotics for proven infection within 1 week prior to study entry or signs and symptoms consistent with an active infection or fever > 38.1 C.
The participant has received a recent (within 30 days of enrollment) or is receiving concurrent yellow fever vaccination.
Presence of fever [oral temperature of 38°C or equivalent] at Baseline. However, this requirement is waived if the subject has a history of fever within in the 24 hours prior to Baseline; or, if the subject reported symptoms of feverishness at some time during the 48 hours prior to Baseline. AND at least 2 out of the following 4:
Recurrent, unexplained fever of greater than 100.5F (38C) without signs of infection
The subject has active infection or fever > 38.5 degrees Celsius (C) within 3 days prior to first dose of study drug
fever (>38ºC) of unclear etiology
Patients must have no fever or evidence of infection or other coexisting medical condition that would preclude epidural placement
Presence of fever (>= 100 degrees F)
Moderate or severe acute illness with or without fever
Patients must have no fever or evidence of infection or other coexisting medical condition that would preclude epidural placement
An active infection or with a fever ? 38.5°C
Acute disease and/or fever at the time of enrolment.
Patients should not have either CT scanning or B-WARM if they have a fever at the time\r\n* Fever should be worked up and treated as appropriate\r\n* Patients should be afebrile for 24 hours prior to scanning or B-WARM therapy
Fever (> 38° Celsius [C]), chills or rigor
Patients should have body Temperature <= 38.0 degrees C.
Any infection requiring parenteral antibiotic therapy or causing fever (temperature > 100.5 degrees Fahrenheit [F] or 38.1 degrees Celsius [C]) within 1 week prior to registration
Active infection requiring treatment or an unexplained febrile (> 101.5 degrees Fahrenheit [F]) illness
Patients with an active infection requiring intravenous treatment or having an unexplained febrile illness (time to maximum concentration [Tmax] > 99.5 degrees Fahrenheit [F], 37.5 degrees Celsius [C])
Patients with an active infection requiring treatment or having an unexplained febrile illness
Febrile patients
Patients with an active infection requiring intravenous treatment or having an unexplained febrile illness (maximum temperature [Tmax] > 99.5 degrees Fahrenheit [F])
Patients with severe, active co-morbidity, defined as follow:\r\n* Patients with an active infection requiring intravenous treatment or having an unexplained febrile illness (maximum temperature [Tmax] > 99.5 degrees Fahrenheit [F]/37.5 degrees Celsius [C])\r\n* Patients with known immunosuppressive disease or known human immunodeficiency virus infection\r\n* Patients with unstable or severe intercurrent medical conditions such as severe heart disease (New York Heart Association class 3 or 4)\r\n* Patients with known lung (forced expiratory volume in 1 second [FEV1] < 50%) disease or uncontrolled diabetes mellitus\r\n* Patients with albumin allergy\r\n* Patients with gadolinium allergy
Active infection requiring intravenous antibiotics or an unexplained febrile (> 101.5 degrees Fahrenheit [F]) illness
Active infection requiring treatment or an unexplained febrile (> 101.5 degrees Fahrenheit [F]) illness
Active infection requiring treatment or an unexplained febrile (> 101.5 degrees Fahrenheit [F]) illness
Unexplained febrile illness
Patients with core body temperature > 37 degrees Celsius (C) at completion of cytoreductive surgery and prior to HIPEC
Any infection requiring parenteral antibiotic therapy or causing fever (temperature > 100.5 degrees Fahrenheit [F] or 38.1 degrees Celsius [C]) within 1 week prior to registration
Patients with an active infection or with a fever >= 101.3 degrees Fahrenheit (F) within 3 days of the first scheduled day of protocol treatment
Active infection requiring systemic antibiotic therapy or causing fever (temp > 100.5 degrees Fahrenheit [F] or 38.1 degrees Celsius [C]) within 1 week prior to dosing with AZD1775
Patient has active infection at time of study entry that require systemic antibiotics and/or with an oral temperature of >= 38.3 degrees C (100.9 degrees Fahrenheit [F]) within 5 days of first treatment
Documented infections or known oral temperature > 38.2 degrees Celsius (C) fewer than 72 hours prior to receiving study treatment or systemic infection requiring chronic maintenance; the start of treatment may be delayed
Unexplained febrile illness
Active infection or unexplained fever > 38.5 degrees Celsius (C) (> 101.3 degrees Fahrenheit [F]) within 2 weeks prior to enrollment
Participant has an active infection or unexplained fever > 38.5 degrees Celsius (C) (101.3 degrees Fahrenheit [F])
Patients with an active infection requiring treatment or an unexplained febrile (> 101.5 degrees Fahrenheit [F]) illness
Temperature =< 38° Celsius (C) (=< 100.4° Fahrenheit [F])
Temperature =< 38 Celsius (C) (=< 100.4 Fahrenheit [F])
Normal body temperature (=< 100 degrees F)
Acute febrile illness
Fever of > 101 degrees Fahrenheit (F) or blood pressure (BP) > 180/95
Patients with ongoing febrile illness or documented infectious disease
Evidence of uncontrolled infection (oral/oropharyngeal or systemic), including oral herpes or unexplained febrile illness (? 99.5F /37.5C) requiring systemic anti-infectives, within 7d of treatment Day 1.
